JCO Impact Factor

JCO's IF has more than doubled since 2012, up from 18.0 to 44.7. That trajectory reflects the expansion of clinical oncology trials, the rise of immunotherapy and targeted therapy publications, and JCO's increasing selectivity. The 2024 dip from the 2022 peak looks less like a journal-quality collapse than a post-pandemic citation normalization pattern. The current 44.7 value moves JCO back up from the prior 41.9 row, but authors should still treat the year-by-year table as planning context rather than a formal bibliometrics citation table.

Rank rows are easier to misuse than the headline JIF because categories and denominators change. Use the current row for current-facing copy, and use JCR directly before citing historical category ranks.

JCO covers the full spectrum of clinical oncology. The journal publishes original research articles (primarily phase II/III clinical trials), reviews, editorials, special articles, and ASCO clinical practice guidelines. The editorial board prioritizes studies that directly inform treatment decisions, randomized trials with survival endpoints, large prospective cohort studies, and meta-analyses that change clinical practice. JCO also publishes translational research when it has clear clinical implications, particularly biomarker-driven studies that inform patient selection for therapies. ASCO guidelines published in JCO are among the most-cited items in oncology.

JCO's IF of 44.7 says the journal sits in the elite citation tier for clinical oncology, but it does not mean every strong oncology paper belongs there. The number is partly a signal of field citation density: practice-changing trials, ASCO guideline papers, and definitive treatment-sequencing articles are cited quickly because clinicians, guideline panels, grant writers, and review authors keep returning to them.

The better author question is not "is 44.7 high enough?" It is whether the paper has a JCO-shaped contribution. A phase 3 trial with a patient-relevant endpoint, mature follow-up, and treatment-decision consequence can justify JCO even when the topic is disease-specific. A beautiful mechanistic paper without a clinical dataset usually cannot. A real-world evidence study can fit if it resolves a decision oncologists face, but a large dataset that only confirms an already-settled trial result will usually look weaker than the JIF suggests.

Use the metric as a tier marker, then pressure-test endpoint maturity, patient selection, biomarker logic, safety, quality of life, and whether the abstract tells practicing oncologists what changes.

JCO's Scopus profile reinforces the JCR picture. The 2024 CiteScore is 38.9 and the SJR is 11.205, placing JCO at rank 9 out of 415 oncology journals. The SNIP of 5.983 shows that JCO's citation performance isn't inflated by oncology's naturally high citation density, it's genuinely exceptional even after field normalization. For institutions that weight Scopus-style indicators, these numbers confirm JCO's position as one of the strongest clinical oncology venues in the world.

For clinical oncologists, JCO is the default citation target for many trial results and ASCO guideline papers. A practice-changing phase 3 trial published in JCO can become a durable reference, but the deeper JCR rows should not be copied from an old screenshot or media kit. For current-facing copy, quote 44.7 from the 2026 release and verify every secondary row at the moment of formal use.

JCO's editorial culture is shaped by ASCO (American Society of Clinical Oncology):

1. Practice-changing potential. JCO publishes results that directly inform treatment decisions. Reviewers ask: "Would an oncologist change what they do based on this paper?" If the answer is "probably not yet," the paper likely belongs in a specialty oncology journal.

1. Rigorous trial design. JCO is the gold standard for phase 2-3 clinical trial results. Reviewers scrutinize randomization, endpoints, sample size justification, and intent-to-treat analysis with unusual thoroughness.

1. Biomarker and correlative science. Pure molecular biology without clinical context doesn't fit JCO. But trial papers that include biomarker correlatives (predictive markers, resistance mechanisms) are favored over those that don't.

1. Real-world evidence standards. JCO increasingly publishes observational and real-world evidence studies, but holds them to high methodological standards (STROBE compliance, sensitivity analyses, clear limitations).

1. Patient-reported outcomes. Reviewers notice when quality-of-life data is missing. Including PRO data strengthens any JCO submission.

A JCO submission readiness check can assess whether your trial results or oncology study meets JCO's clinical impact threshold.

The oncology journal landscape is unusually crowded at the top. There are more IF 30+ oncology journals than in almost any other medical specialty. Understanding where JCO sits (and what it does differently from journals with similar or higher IFs) matters for submission strategy.

JCO's JCI of 6.68 confirms it's not just riding oncology's naturally high citation rates, it's genuinely exceptional after field normalization. The journals above JCO in raw IF are either review-only (CA, Nature Reviews) or serve different editorial missions (Annals of Oncology is ESMO's flagship the way JCO is ASCO's). For original clinical oncology research, JCO and Lancet Oncology are the two realistic targets, with Annals of Oncology as the European alternative.

JCO papers aren't created equal when it comes to citation impact. The 44.7 IF is an average across all article types, but the spread between a guideline-changing phase 3 trial and a retrospective cohort study is enormous. Here's what actually predicts whether a JCO paper gets cited heavily.

The single strongest citation predictor is guideline impact. When a JCO paper leads to an ASCO or NCCN guideline update, every oncologist writing a protocol, grant, or review paper cites it. Phase 3 trials with overall survival endpoints in common cancers that include biomarker analysis are the papers that hit 200+ citations within two years.

Papers without biomarker correlatives are increasingly at a disadvantage. JCO's editorial board has pushed hard for translational science integration, and reviewers now routinely ask why a clinical trial paper doesn't include predictive marker data. Including even exploratory biomarker analysis strengthens both the acceptance odds and the long-term citation trajectory.

A JCO submission readiness check can evaluate whether your oncology study has the clinical impact elements that JCO reviewers prioritize.

Most people think of JCO as a clinical trials journal. It is, but the papers that drive the biggest citation numbers are often something else entirely: ASCO Clinical Practice Guidelines, Provisional Clinical Opinions, and Quality of Care articles.

ASCO guidelines published in JCO are among the most-cited documents in all of oncology. For mid-career oncologists, joining an ASCO guideline panel isn't just service work, it's a path to JCO authorship that doesn't require running your own phase 3 trial. Quality of Care articles are an underused submission category. JCO publishes research on cancer care delivery, health equity, and value-based oncology that doesn't need to be a randomized trial.

If your work addresses how oncology care is delivered rather than what treatment works, this category is worth exploring.

In our review work on JCO-targeted manuscripts, and in our review of oncology submissions more broadly, we observe that the metric is rarely the real blocker. The manuscript usually knows JCO is prestigious. The weaker part is whether the abstract, endpoint table, biomarker plan, statistical analysis, and cover letter prove that the paper belongs in ASCO's clinical decision stream. These are the patterns we see most often.

JCO biomarker-free phase 2 and 3 trial reports.

JCO's editorial board has documented its push for translational science integration. Reviewers now routinely flag trials that enroll patients, report efficacy and toxicity endpoints, and submit without any predictive biomarker data, even exploratory marker analysis.

The framing this triggers: "Why doesn't this trial tell us which patients benefit?" A phase 2 single-arm trial showing 42% objective response rate in unselected patients is technically publication-worthy data, but JCO editors increasingly ask whether the manuscript advances patient selection or just documents a response rate that will require a larger trial to confirm.

Including even preliminary biomarker analysis from a defined patient subset, or pre-specifying why marker-unselected enrollment was the right design choice, is the difference between a manuscript that clears the desk and one that doesn't.

JCO retrospective analyses confirming established clinical rankings. JCO accepts retrospective real-world evidence studies, but the bar is "practice-changing real-world data," not "large dataset confirming what randomized trials already established." A retrospective analysis of claims data showing that Drug A has better adherence than Drug B among Medicare patients is potentially publishable. A retrospective analysis of the same population showing Drug A has similar survival to Drug B when the RCT already showed this is not.

The distinction is whether the retrospective data resolves a clinical uncertainty or merely reproduces a known result in a real-world sample. Reviewers ask: "Would an oncologist change anything based on this?"

JCO mechanistic manuscripts misrouted to a clinical journal. JCO is ASCO's clinical flagship. Papers that are primarily translational, a new immune evasion mechanism in NSCLC, a cell-line study of resistance pathways, a mouse model of combination therapy, will be returned, regardless of oncological relevance. The ASCO family directs these papers to Cancer Research or Cancer Cell. If the manuscript's primary contribution is a biological mechanism without a clinical dataset, it needs a different venue before reaching JCO.

JCO cover letters that sell prestige instead of practice change. The cover letter should not lead with "JCO is high impact." Editors already know that. The stronger cover letter names the patient group, primary endpoint, treatment-decision consequence, and why ASCO readers need this evidence now. When the cover letter only repeats the impact factor, it often exposes that the team has not yet written the clinical-practice argument clearly enough.

JCO endpoint packages where the abstract outruns the data. The most common near-miss is not a bad study. It is a conclusion that sounds guideline-ready while the endpoint maturity, follow-up window, subgroup power, or confidence intervals still support a more cautious claim. In those cases, we usually revise the abstract claim, endpoint table, limitations paragraph, and cover-letter pitch together so the manuscript does not promise more clinical certainty than the data can carry.

A JCO submission readiness check can confirm whether the manuscript's evidence package meets JCO's clinical bar before you commit to the submission.